摘要
目的研究虹膜夹型有晶状体眼人工晶状体（ICPIOL）矫治高度近视眼的安全性和有效性。方法高度近视眼患者13例（25只眼），等效球镜度数（SE）（-15．63±3．51）D植入ICPIOL。术后随访1年，观察手术前后的视力、屈光状态、眼压、角膜、前房、瞳孔、ICPIOL和晶状体、眼底情况，并进行比较。结果与术前比较，术后1d、7d及1、3、6、12个月的裸眼视力（UCVA）、最佳矫正视力（BCVA）和SE显著改善。术后1年时，所有眼UCVA均1〉0．5，其中〉10．8有71．43％；BCVA未见下降，95．24％提高≥2行，4．76％提高1行；所有眼的屈光状态均稳定在±2．00D，其中±0．50D有71．43％，±1．00D有85．71％。术后1年角膜内皮细胞丢失无统计学意义。除了7只眼术中在夹持虹膜固定ICPIOL时有轻度虹膜脱色素，1只眼主切口渗漏于术后第2天重新缝合外，未见其他并发症发生。结论ICPIOL矫治高度近视术后1年内安全、有效。远期效果尚待进一步观察。
Objective To investigate the efficacy and safety of an iris-claw phakic intraocular lens （ICPIOL） implantation for high myopia. Methods A consecutive group of 25 eyes in 13 patients with - 7.88 to - 22. 88 diopters （D） of myopia was implanted with the Verisys ICPIOL （ AMO ）, and was examined preoperatively and 1, 7 days, 1, 3, 6, and 12 months postoperatively. Uncorrected visual acuity （UCVA）, best corrected visual acuity （BCVA）, manifest refraction, intraocular pressure, and complications were evaluated. Results The implantation was successful in all of 25 eyes. Compared with preoperative data, UCVA, BCVA, and spherical equivalent （SE） were improved significantly. At 12-month postoperatively, UCVA was 0. 5 or better in all eyes, in which the UCVA in 71.43% eyes was 0. 8 or higher; No loss of BCVA was found, 2 lines of BCVA improvement was obtained in 95.24% of patients with ICPIOL, and 1 line BCVA improvement was seen in 4. 76% of patients; the power of refraction in all eyes implanted with ICPIOL was stabilized within the variation of ＋ 0.50D （71.43%）, and ＋ 1.00D （85.71% ）. The corneal endothelial loss was insignificant. No severe complications occurred. Conclusions At short-term foUow-up, the implantation of the ICPIOL proved to be safe and effective for the correction of myopia in phakic eyes. However, longer follow-up with larger numbers of patients is necessary to evaluate long-term complications.
出处
《中华眼科杂志》
CAS
CSCD
北大核心
2007年第4期336-339,共4页
Chinese Journal of Ophthalmology
关键词
晶体
人工
眼外科手术
近视
Lenses, intraocular
Ophthalmologic surgical procedures
Myopia
